Tumor lysis syndrome primary prevention: Difference between revisions
Jump to navigation
Jump to search
(Mahshid) |
|||
| (9 intermediate revisions by one other user not shown) | |||
| Line 3: | Line 3: | ||
{{CMG}}{{AE}} {{MJK}} | {{CMG}}{{AE}} {{MJK}} | ||
==Overview== | ==Overview== | ||
Effective measures for the primary prevention of tumor lysis syndrome include [[allopurinol]], [[rasburicase]], and | Effective measures for the primary prevention of tumor lysis syndrome include [[allopurinol]], [[rasburicase]], and [[intravenous]] hydration. | ||
==Prevention== | ==Prevention== | ||
Before initiating chemotherapy for cancer patients, especially lymphomas and leukemias, should receive the following: | Before initiating chemotherapy for cancer patients, especially lymphomas and leukemias, patients should receive the following:<ref name="JonesWill2015">{{cite journal|last1=Jones|first1=Gail L|last2=Will|first2=Andrew|last3=Jackson|first3=Graham H|last4=Webb|first4=Nicholas J A|last5=Rule|first5=Simon|title=Guidelines for the management of tumour lysis syndrome in adults and children with haematological malignancies on behalf of the British Committee for Standards in Haematology|journal=British Journal of Haematology|volume=169|issue=5|year=2015|pages=661–671|issn=00071048|doi=10.1111/bjh.13403}}</ref> | ||
{| style="border: 0px; font-size: 90%; margin: 3px; width: 600px" align=center | |||
|valign=top| | |||
|+ | |||
! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Patient population}} | |||
! style="background: #4479BA; width: 400px;" | {{fontcolor|#FFF|Treatment}} | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" | | |||
Low risk | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
*Adequate [[intravenous]] hydration to maintain a high urine output (> 2.5 L/day) | |||
*Alkalinization of urine is not recommended.<ref name="pmid9607427">{{cite journal| author=Ten Harkel AD, Kist-Van Holthe JE, Van Weel M, Van der Vorst MM| title=Alkalinization and the tumor lysis syndrome. | journal=Med Pediatr Oncol | year= 1998 | volume= 31 | issue= 1 | pages= 27-8 | pmid=9607427 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=9607427 }} </ref> | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" | | |||
Intermediate risk | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
*[[Allopurinol]] | *[[Allopurinol]] | ||
*[[Rasburicase]] | :*Adults dosing: 200-400mg/m2/day in 1-3 divided doses; maximum dose is 800mg/day | ||
* | :*Infants weighing less than 10kg: 3.3mg/kg every 8 hours | ||
* | |- | ||
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" | | |||
High risk | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
*[[Rasburicase]] | |||
:*0.2mg/kg for 5-7 days | |||
:*A single dose of 3 mg may be used in high risk patients | |||
:*Contraindicated in patients with glucose 6 phosphate dehydrogenase ([[G6PD]]) deficiency | |||
|- | |||
| | |||
|} | |||
==References== | ==References== | ||
| Line 20: | Line 47: | ||
[[Category:Blood]] | [[Category:Blood]] | ||
[[Category:Hematology]] | [[Category:Hematology]] | ||
[[Category:Up-To-Date]] | |||
[[Category:Oncology]] | |||
[[Category:Medicine]] | |||
Latest revision as of 17:27, 27 November 2017
|
Tumor lysis syndrome Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Tumor lysis syndrome primary prevention On the Web |
|
American Roentgen Ray Society Images of Tumor lysis syndrome primary prevention |
|
Risk calculators and risk factors for Tumor lysis syndrome primary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Mohamad Alkateb, MBBCh [2]
Overview
Effective measures for the primary prevention of tumor lysis syndrome include allopurinol, rasburicase, and intravenous hydration.
Prevention
Before initiating chemotherapy for cancer patients, especially lymphomas and leukemias, patients should receive the following:[1]
| Patient population | Treatment |
|---|---|
|
Low risk |
|
|
Intermediate risk |
|
|
High risk |
|
References
- ↑ Jones, Gail L; Will, Andrew; Jackson, Graham H; Webb, Nicholas J A; Rule, Simon (2015). "Guidelines for the management of tumour lysis syndrome in adults and children with haematological malignancies on behalf of the British Committee for Standards in Haematology". British Journal of Haematology. 169 (5): 661–671. doi:10.1111/bjh.13403. ISSN 0007-1048.
- ↑ Ten Harkel AD, Kist-Van Holthe JE, Van Weel M, Van der Vorst MM (1998). "Alkalinization and the tumor lysis syndrome". Med Pediatr Oncol. 31 (1): 27–8. PMID 9607427.